Advertisements


Roche"s Child Arthritis Drug"s New Formulation Gets FDA Nod

Zacks.....»»

Category: topSource: redinewsSep 14th, 2018

Roche Gets FDA Approval for New Formulation of Asthma Drug

Roche (RHHBY) receives FDA approval for a dose prefilled syringe (PFS) formulation of its asthma drug, Xolair. Roche Holding AG RHHBY announced that the FDA has approved expansion prefilled .....»»

Category: dealsSource: nytOct 1st, 2018

Trump Drug-Prices Plan Could Hit 2 Pharma Stocks

Roche and Bristol-Myers Squibb are most exposed among large-cap pharmaceuticals firms to Medicare Plan B sales, notes Credit Suisse......»»

Category: topSource: barronsFeb 7th, 2019

Roche, joining rivals, donates hemophilia drug to boost access

Switzerland's Roche will donate its new hemophilia A drug Hemlibra to a World Hemophilia Federation program, it said on Wednesday, joining rivals who also back the effort to help patients in developing countries who face treatment hurdles......»»

Category: topSource: reutersFeb 6th, 2019

Roche, Biogen, And The Achilles" Heel Of Alzheimer"s Drug Development

Roche, Biogen, And The Achilles" Heel Of Alzheimer"s Drug Development.....»»

Category: topSource: seekingalphaFeb 4th, 2019

Analysts defend Biogen after Roche discontinues late-stage Alzheimer’s drug trials

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 30th, 2019

Roche May Have A Competing Drug For A Rare Disease

Roche May Have A Competing Drug For A Rare Disease.....»»

Category: topSource: seekingalphaDec 26th, 2018

Nabriva files 2 NDAs seeking approval for experimental pneumonia treatment

Nabriva Therapeutics on Thursday submitted two new drug applications with the Food and Drug Administration seeking marketing approval for intravenous and oral formulation of Lefamulin to treat community-acquired bacterial pneumonia in adults. “The .....»»

Category: topSource: bizjournalsDec 20th, 2018

Roche Executive to Be Named Gilead CEO

Gilead Sciences is planning to hire industry veteran Daniel O’Day to take the helm and help the drug company revive sales and recover from a disappointing deal......»»

Category: topSource: wsjDec 10th, 2018

The Wall Street Journal: Gilead Sciences plans to hire Roche executive Daniel O’Day as its next CEO

Gilead Sciences Inc. is planning to hire industry veteran Daniel O’Day to take the helm and help the drug company revive sales and recover from a disappointing deal, according to people familiar with the matter......»»

Category: topSource: marketwatchDec 9th, 2018

Exelixis Initiates Pivotal Liver Cancer Study on Cabometyx

Exelixis (EXEL) and its partner announce initiation of a pivotal study to evaluate its kidney cancer drug, Cabometyx, in combination with Roche's Tecentriq in liver cancer. Exelixis, Inc. EXEL along with its French partner, Ipse.....»»

Category: worldSource: nytDec 6th, 2018

Brainstorm Health: Roche Jecure Deal, Amazon AWS and Amgen, Vertex CF Drug

Brainstorm Health Daily: November 27, 2018 Hello, readers. Unfortunately, I’m embroiled in a bit of a post-Thanksgiving break travel nightmare at the moment, so we’re going to have t.....»»

Category: europeSource: fortuneNov 27th, 2018

AbbVie expects double-digit earnings growth in 2019

AbbVie Inc said on Friday it was confident that its earnings would grow in the double digits in 2019, in spite of the launch of biosimilar versions of its best-selling rheumatoid arthritis drug Humira in the European Union......»»

Category: topSource: reutersNov 2nd, 2018

Biogen (BIIB) Q3 Earnings Coming Up: What"s in the Cards?

On the third-quarter call, investor focus will be on the impact of Roche's newly launched drug, Ocrevus on Biogen's (BIIB) MS franchise and Spinraza's performance. Biogen Inc. BIIB will report third-quarter 2018 re.....»»

Category: smallbizSource: nytOct 19th, 2018

FDA Accepts Application for AbbVie"s Imbruvica in Specific Blood Cancers

The drug will be used together with Roche's GazyvaRelated Stocks: ABBV, XSWX:RO,.....»»

Category: dealsSource: nytOct 18th, 2018

The Daily Biotech Pulse: Eiger"s Lymphoedema Drug Study Fails, Roche"s Sales Rise

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 16) read more.....»»

Category: blogSource: benzingaOct 17th, 2018

The Daily Biotech Pulse: Eiger"s Lymphoedema Drug Study Fails, Roche"s Sales Rise

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 16) Endo International PLC (NASDAQ: ENDP) Krys.....»»

Category: earningsSource: benzingaOct 17th, 2018

Roche Announces Positive Data on Breast Cancer Drug Kadcyla

Roche's (RHHBY) breast cancer drug Kadcyla, in a late-stage study in patients suffering from HER2-positive eBCmet, met its goal. Roche RHHBY announced encouraging results from a phase III st.....»»

Category: smallbizSource: nytOct 16th, 2018

Roche (RHHBY) Presents Encouraging Data on MS Drug Ocrevus

Roche's (RHHBY) MS drug Ocrevus lowers disability progression over five years in relapsing/primary progressive multiple sclerosis with an early initiation of treatm.....»»

Category: smallbizSource: nytOct 10th, 2018

Ionis"s stock surges after Roche collaboration, which could be worth up to $759 million

Shares of Ionis Pharmaceuticals Inc. rallied 4.7% in premarket trade, after the drug discovery company announced a new collaboration deal with Switzerland-based Roche Holding AG , which could be.....»»

Category: topSource: marketwatchOct 10th, 2018

Roche (RHHBY) Presents Encouraging Data on SMA Drug Risdiplam

Roche (RHHBY) reports encouraging data from two pivotal studies -- FIREFISH and SUNFISH -- on ris.....»»

Category: dealsSource: nytOct 4th, 2018